Compare Agilysys Inc (AGYS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs BIO-TECHNE Corp — how do they compare? Agilysys Inc trades at $106.06 (market cap $3.02B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 3.7× Agilysys Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | TECH | |
|---|---|---|
Market Cap | $3.02B | $11.24B |
Sector | Technology | Health |
52-Week High | $141.12 | $72.29 |
52-Week Low | $62.19 | $43.31 |
Enterprise Value | $2.92B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $108.58, up 0.93% with strong bullish momentum supported by recent earnings beats and positive analyst sentiment. The stock shows robust fundamental performance with Q1 2026 EPS of $0.63 beating expectations and record subscription revenue growth. Technical indicators suggest bullish momentum with the current price near pivot point resistance at $108, while moving averages signal continued upward trend potential.
The outlook remains positive with 100% analyst buy ratings and a $118.33 consensus price target representing 9% upside. Key catalysts include continued subscription growth and Marriott deployment progress, though elevated valuation multiples (P/E 70.45) and competitive pressures in hospitality software present risks requiring monitoring of execution consistency.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
